| Senvelgo 15 mg/ml - 12 ml • liki24.co.uk | 93.60 RON |
| Senvelgo 15 mg/ml - 12 ml • liki24.at | 112.30 RON |
| Senvelgo 15 mg/ml - 12 ml • liki24.es | 112.30 RON |
For the reduction of hyperglycemia in cats with non-insulin dependent diabetes mellitus. Ingredients per ml: Velagliflozin 15 mg (equivalent to velagliflozin L-proline H2O 20.1 mg). Excipients: Ethanol 96%, Propylene glycol, Citric acid monohydrate, Sodium hydroxide, honey flavor, purified water. Intended for: Cats. Method of administration: Oral administration. Presentation form: 12 ml bottle. Dosage: The recommended dose is 1 mg/kg body weight, administered once daily. For cats previously treated with insulin/another antidiabetic drug, the dosing regimen is the same. When switching from insulin, omit the evening dose of insulin the day before starting velagliflozin. The solution should be withdrawn using the dosing syringe provided in the package. The syringe fits onto the bottle and has graduations corresponding to body weight in kg. The veterinary medicinal product can be administered either directly into the oral cavity or with a small amount of food. The veterinary medicinal product should be administered at approximately the same time each day. If a dose is missed, it should be administered as soon as possible on the same day. Possible adverse effects: The most common clinical side effects that are reported are diarrhea, polyuria, weight loss, or dehydration. The least common side effects are hypersalivation or urinary tract infections. Precautions: The safety or efficacy of the veterinary medicinal product has not been established in cats less than 1 year of age. Urinary tract infections may occur due to glucosuria, caused by diabetes mellitus or as an effect of velagliflozin. If adverse effects of treatment persist (e.g. diarrhea), velagliflozin should be discontinued and alternative treatment for DM should be considered. Storage method: Store in a place protected from moisture and direct sunlight, at temperatures up to 25°C. Shelf life after first opening the bottle: 6 months. Product compliance information Product compliance information Product safety Manufacturer information Personal information Product safety information Currently, product safety information is not available. Manufacturer information Currently, information about the manufacturer is not available. Responsible person information Currently, information about the person responsible is not available. n Size: Small, Medium, Large Age: Junior, Adult, Senior Presentation type: Bottle Action: Diabetes mellitus Brand Name: Boehringer Ingelheim n Quantity: 12 ml